1
|
Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis
via
dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer 2019; 145:979-993. [DOI: 10.1002/ijc.32180] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 12/19/2018] [Accepted: 01/17/2019] [Indexed: 12/19/2022]
Affiliation(s)
- Gangyang Wang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Mengxiong Sun
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Yafei Jiang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Tao Zhang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Wei Sun
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Hongsheng Wang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Fei Yin
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zhuoying Wang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Weilin Sang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Jing Xu
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Min Mao
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Dongqing Zuo
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zifei Zhou
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Chongren Wang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zeze Fu
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zongyi Wang
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zhenfeng Duan
- Department of OrthopaedicsDavid Geffen School of Medicine at UCLA Los Angeles CA
| | - Yingqi Hua
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| | - Zhengdong Cai
- Department of Orthopaedics, Shanghai General HospitalShanghai Jiao Tong University School of Medicine Shanghai China
- Shanghai Bone Tumor Institute Shanghai China
| |
Collapse
|
2
|
Chen C, Tian A, Zhao M, Ma X. Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/β-catenin signaling. Cancer Gene Ther 2018; 26:83-93. [PMID: 30140042 DOI: 10.1038/s41417-018-0041-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Revised: 06/06/2018] [Accepted: 07/07/2018] [Indexed: 12/14/2022]
Abstract
The VHL tumor suppressor gene is frequently inactivated in several human tumors, including bone sarcomas. We previously identified that reduced expression of VHL protein is implicated in sarcomagenesis. However, the underlying biological functions of restored VHL protein expression have not been clearly elucidated in bone sarcomas. Here we initially constructed a recombinant adenovirus 5-VHL vector (Ad5-VHL) and evaluated its expression in bone sarcomas, and antitumor activity in vitro and in vivo. We found that the adenovirus-mediated increase of VHL significantly suppresses bone sarcoma cell growth, attributed to induction of apoptosis mediated by increased caspase-3 activity and modulated Bcl-2 protein family. This suppression effect involves inhibition of Wnt/β-catenin signaling and upregulation of GSK-3β. Moreover, Ad5-VHL showed a dramatic antitumor effect on a chondrosarcoma xenograft model. These findings establish that Ad5-VHL suppresses bone sarcoma cell growth by inhibiting Wnt/β-catenin signaling, and may be a novel target for gene-based therapy of bone sarcomas.
Collapse
Affiliation(s)
- Changbao Chen
- Department of Spinal Surgery, Tianjin Hospital, 406 Jiefang South Road, Tianjin, 300211, P.R. China
| | - Aixian Tian
- Department of Orthopedics Institute, Tianjin Hospital, 406 Jiefang South Road, Tianjin, 300211, P.R. China
| | - Meng Zhao
- Department of Medical Laboratory, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Tianjin, 300060, P.R. China
| | - Xinlong Ma
- Department of Spinal Surgery, Tianjin Hospital, 406 Jiefang South Road, Tianjin, 300211, P.R. China.
| |
Collapse
|
3
|
Hu X, Zhang C, Zhang Y, Hong CS, Chen W, Shen W, Wang H, He J, Chen P, Zhou Y, Shi C, Chu T. Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma. Oncotarget 2017; 8:53210-53225. [PMID: 28881805 PMCID: PMC5581104 DOI: 10.18632/oncotarget.18290] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 05/10/2017] [Indexed: 11/25/2022] Open
Abstract
Osteosarcoma is a kind of primary malignant bone tumor with the highest incidence and an extraordinarily poor prognosis and early pulmonary metastasis formation as a frequent occurrence. Transcriptional positive coactivator 4 (PC4) has multiple functions in DNA replication, transcription, repair and chromatin organization, even in tumorigenesis. However, the precise function of PC4 in osteosarcoma is still unclear and controversial. In this paper we found PC4 was upregulated in patient-derived osteosarcoma tissues compared to normal. Moreover, higher expression of PC4 was correlated with poorer overall survival and advanced clinicopathological tumor staging. Down regulation of PC4 in the highly metastatic osteosarcoma cells reduced the malignant behaviors in vitro and in vivo. Analyzing the downstream genes affected obviously by shPC4 with RNA sequencing, we found knocking down PC4 will inhibit the propensity for lung metastasis through transcriptional suppression of MMPs pathways. Taken together, PC4 may be an attractive therapeutic strategy for osteosarcoma, especially in preventing lung metastasis formation.
Collapse
Affiliation(s)
- Xu Hu
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Chao Zhang
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Ying Zhang
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Christopher S Hong
- The Ohio State University, College of Medicine, Columbus, OH, 43210, USA
| | - Wugui Chen
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Weiwei Shen
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Hongkai Wang
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Jianrong He
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Pei Chen
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Yue Zhou
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Chunmeng Shi
- Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Third Military Medical University, Chongqing, 400038, China
| | - Tongwei Chu
- Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| |
Collapse
|
4
|
Chen C, Zhao M, Tian A, Zhang X, Yao Z, Ma X. Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 2016; 6:17570-83. [PMID: 25999350 PMCID: PMC4627329 DOI: 10.18632/oncotarget.4100] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 03/30/2015] [Indexed: 12/25/2022] Open
Abstract
Bone sarcomas such as osteosarcoma and chondrosarcoma are frequently refractory to conventional chemotherapy and radiotherapy that exhibit poor prognosis. The Wnt signaling are evolutionarily conserved and implicated in cell proliferation and sarcomagenesis. However, the potential role of the Wnt signaling in bone sarcomas is still unclear. Here we demonstrate aberrant activation of Wnt/β-catenin signaling in bone sarcoma cells, involving an autocrine Wnt signaling loop with upregulation of specific Wnt ligands and receptors. Activation of Wnt/β-catenin signaling with Wnt3a or GSK-3β inhibitor drives the proliferation of bone sarcoma cells, whereas downregulation of activated Wnt signaling with dnTCF4 or siLEF1 suppresses bone sarcoma proliferation and induces cell cycle arrest. Taken together, our findings establish the evidence that aberrant activation of Wnt/β-catenin pathway involving an autocrine Wnt singaling drives the proliferation of bone sarcoma cells, and identify the autocrine activation of the Wnt/β-catenin signaling as a potential novel therapeutic target for bone sarcomas.
Collapse
Affiliation(s)
- Changbao Chen
- Department of Spinal Surgery, Tianjin Hospital, Tianjin, P. R. China
| | - Meng Zhao
- Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P. R. China
| | - Aixian Tian
- Department of Medical Laboratory, Tianjin Hospital, Tianjin, P. R. China
| | - Xiaolin Zhang
- Department of Spinal Surgery, Tianjin Hospital, Tianjin, P. R. China
| | - Zhi Yao
- Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, P. R. China
| | - Xinlong Ma
- Department of Spinal Surgery, Tianjin Hospital, Tianjin, P. R. China
| |
Collapse
|
5
|
Chen J, Yan D, Wu W, Zhu J, Ye W, Shu Q. MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. Oncol Rep 2016; 35:3285-92. [PMID: 27035216 DOI: 10.3892/or.2016.4719] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 12/30/2015] [Indexed: 11/05/2022] Open
Abstract
MicroRNAs, which serve as post-transcriptional modulators of numerous genes, have been found to be important regulators during the pathogenesis of osteosarcoma. This study demonstrates for the first time that microRNA-130a (miR-130a) is significantly upregulated in osteosarcoma, and associated with the metastasis of osteosarcoma. Elevated level of miR-130a was closely correlated with poor clinical features and prognosis of osteosarcoma patients. In vitro assays revealed that miR-130a could potentiate the migration, invasion and the epithelial-mesenchymal transtion (EMT) of osteosarcoma cells. Moreover, phosphatase and tensin homolog (PTEN) was confirmed as not only a direct downstream target but also a functional mediator of miR-130a. MiR-130a exerted promoting effects on metastatic behavior and EMT of osteosarcoma cells through suppressing PTEN expression. Based on these findings, we conclude that miR-130a is a promising prognostic biomarker for osteosarcoma patients, and targeting miR-130a may be a potential treatment option for osteosarcoma patients with metastasis.
Collapse
Affiliation(s)
- Jiansong Chen
- Department of Orthopaedics, Children's Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
| | - Dingding Yan
- Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P.R. China
| | - Weiliang Wu
- Department of Orthopaedics, Children's Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
| | - Jian Zhu
- Department of Orthopaedics, Children's Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
| | - Wensong Ye
- Department of Orthopaedics, Children's Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
| | - Qiang Shu
- Department of Tumor Surgery, Children's Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
| |
Collapse
|
6
|
Li M, Zhu Y, Zhang H, Li L, He P, Xia H, Zhang Y, Mao C. Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells. Sci Rep 2014; 4:7380. [PMID: 25490312 PMCID: PMC4260466 DOI: 10.1038/srep07380] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Accepted: 11/19/2014] [Indexed: 02/07/2023] Open
Abstract
Growing evidence has suggested that inhibitor of growth 4 (ING4), a novel member of ING family proteins, plays a critical role in the development and progression of different tumors via multiple pathways. However, the function of ING4 in human osteosarcoma remains unclear. To understand its potential roles and mechanisms in inhibiting osteosarcoma, we constructed an expression vector pEGFP-ING4 and transfected the human osteosarcoma cells using this vector. We then studied the effects of over-expressed ING4 in the transfected cells on the proliferation, apoptosis and invasion of the osteosarcoma cells. The up-regulation of ING4 in the osteosarcoma cells, arising from the stable pEGFP-ING4 gene transfection, was found to significantly inhibit the cell proliferation by the cell cycle alteration with S phase reduction and G0/G1 phase arrest, induce cell apoptosis via the activation of the mitochondria pathway, and suppress cell invasion through the down-regulation of the matrix metalloproteinase 2 (MMP-2) and MMP-9 expression. In addition, increased ING4 level evoked the blockade of NF-κB signaling pathway and down-regulation of its target proteins. Our work suggests that ING4 can suppress osteosarcoma progression through signaling pathways such as mitochondria pathway and NF-κB signaling pathway and ING4 gene therapy is a promising approach to treating osteosarcoma.
Collapse
Affiliation(s)
- Mei Li
- Department of Orthopedics, Guangdong Key Lab of Orthopaedic Technology and Implant, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Ye Zhu
- Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman OK 73019, USA
| | - Hongbin Zhang
- Department of Medical Research, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Lihua Li
- Department of Orthopedics, Guangdong Key Lab of Orthopaedic Technology and Implant, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Peng He
- Department of Orthopedics, Guangdong Key Lab of Orthopaedic Technology and Implant, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Hong Xia
- Department of Orthopedics, Guangdong Key Lab of Orthopaedic Technology and Implant, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Yu Zhang
- Department of Orthopedics, Guangdong Key Lab of Orthopaedic Technology and Implant, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
| | - Chuanbin Mao
- Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman OK 73019, USA
| |
Collapse
|
7
|
Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas. Tumour Biol 2014; 36:227-31. [PMID: 25230787 DOI: 10.1007/s13277-014-2621-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Accepted: 08/12/2013] [Indexed: 01/06/2023] Open
Abstract
UNLABELLED Cytotoxic T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms are implicated to be associated with susceptibility to bone sarcomas, but published studies have reported inconclusive results. The objective of our study was to conduct a meta-analysis investigating the associations between CTLA-4 gene polymorphisms and risk of bone sarcomas. PubMed and Embase databases were searched for all articles published up to June 2, 2013. Odds ratio (OR) with a 95 % confidence interval (95 % CI) was used to assess the association. Finally, 11 individual studies with a total of 2,951 cases with bone sarcomas and 3,396 controls were included in the meta-analysis. There were four studies on the CTLA-4 49G/A polymorphism, three studies on CTLA-4 318C/T polymorphism, two studies on CTLA-4 1661A/G polymorphism, and two studies on CTLA-4 60A/G polymorphism. Overall, CTLA-4 49G/A polymorphism was obviously associated with risk of bone sarcomas (A vs. G: OR = 1.36, 95 % CI = 1.20-1.54; AA vs. GG: OR = 2.24, 95 % CI = 1.67-2.99; AA vs. AG/GG OR = 2.00, 95 % CI = 1.53-2.62; AA/GA vs. GG: OR = 1.35, 95 % CI = 1.14-1.61). However, CTLA-4 318C/T, 1661A/G, and 60A/G polymorphisms were not associated with risk of bone sarcomas. The current meta-analysis suggests that CTLA-4 49G/A polymorphism is obviously associated with risk of bone sarcomas. More studies are needed to further evaluate the associations between CTLA-4 polymorphisms and risk of bone sarcomas.
Collapse
|
8
|
Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, Heymann D, Redini F, Verrecchia F. Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. Clin Cancer Res 2014; 20:5097-112. [PMID: 25107916 DOI: 10.1158/1078-0432.ccr-13-3191] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastasis is present at diagnosis. Because transforming growth factor-β (TGFβ) has been shown to promote metastasis in many solid tumors, we investigated the effect of the natural TGFβ/Smad signaling inhibitor Smad7 and the TβRI inhibitor SD-208 on osteosarcoma behavior. EXPERIMENTAL DESIGN By using a mouse model of osteosarcoma induced by paratibial injection of cells, we assessed the impact of Smad7 overexpression or SD-208 on tumor growth, tumor microenvironment, bone remodeling, and metastasis development. RESULTS First, we demonstrated that TGFβ levels are higher in serum samples from patients with osteosarcoma compared with healthy volunteers and that TGFβ/Smad3 signaling pathway is activated in clinical samples. Second, we showed that Smad7 slows the growth of the primary tumor and increases mice survival. We furthermore demonstrated that Smad7 expression does not affect in vitro osteosarcoma cell proliferation but affects the microarchitectural parameters of bone. In addition, Smad7-osteosarcoma bone tumors expressed lower levels of osteolytic factors such as RANKL, suggesting that Smad7 overexpression affects the "vicious cycle" established between tumor cells and bone cells by its ability to decrease osteoclast activity. Finally, we showed that Smad7 overexpression in osteosarcoma cells and the treatment of mice with SD208 inhibit the development of lung metastasis. CONCLUSION Taken together, these results demonstrate that the inhibition of the TGFβ/Smad signaling pathway may be a promising therapeutic strategy against tumor progression of osteosarcoma, specifically against the development of lung metastasis.
Collapse
Affiliation(s)
- Audrey Lamora
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France. Inserm Liliane Bettencourt School, Paris, France
| | - Julie Talbot
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Gwenola Bougras
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Jérôme Amiaud
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Marion Leduc
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Julie Chesneau
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Julien Taurelle
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Verena Stresing
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | | | - Marie Françoise Heymann
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Dominique Heymann
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Françoise Redini
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France
| | - Franck Verrecchia
- INSERM, UMR 957, Equipe labellisée Ligue contre le Cancer 2012, Nantes, France. Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France. CHU Hôtel Dieu, Nantes, France.
| |
Collapse
|
9
|
Liu S, Geng P, Cai X, Wang J. Comprehensive Evaluation of the Cytotoxic T-Lymphocyte Antigen-4 Gene Polymorphisms in Risk of Bone Sarcoma. Genet Test Mol Biomarkers 2014; 18:574-9. [PMID: 25000484 DOI: 10.1089/gtmb.2014.0023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Shouying Liu
- Department of Orthopedics, Chinese PLA General Hospital, Beijing, People's Republic of China
- Department of Orthopedics, 253rd Hospital of Chinese PLA, Huhhot, People's Republic of China
| | - Peiliang Geng
- Cancer Center, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing, People's Republic of China
| | - Xu Cai
- Department of Orthopedics, Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Jifang Wang
- Department of Orthopedics, Chinese PLA General Hospital, Beijing, People's Republic of China
| |
Collapse
|
10
|
Radons J. The role of inflammation in sarcoma. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 816:259-313. [PMID: 24818727 DOI: 10.1007/978-3-0348-0837-8_11] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Sarcomas encompass a heterogenous group of tumors with diverse pathologically and clinically overlapping features. It is a rarely curable disease, and their management requires a multidisciplinary team approach. Chronic inflammation has emerged as one of the hallmarks of tumors including sarcomas. Classical inflammation-associated sarcomas comprise the inflammatory malignant fibrous histiocytoma and Kaposi sarcoma. The identification of specific chromosomal translocations and important intracellular signaling pathways such as Ras/Raf/MAPK, insulin-like growth factor, PI3K/AKT/mTOR, sonic hedgehog and Notch together with the increasing knowledge of angiogenesis has led to development of targeted therapies that aim to interrupt these pathways. Innovative agents like oncolytic viruses opened the way to design new therapeutic options with encouraging findings. Preclinical evidence also highlights the therapeutic potential of anti-inflammatory nutraceuticals as they can inhibit multiple pathways while being less toxic. This chapter gives an overview of actual therapeutic standards, newest evidence-based studies and exciting options for targeted therapies in sarcomas.
Collapse
Affiliation(s)
- Jürgen Radons
- Department of Radiotherapy and Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany,
| |
Collapse
|
11
|
Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors. Tumour Biol 2013; 34:3371-5. [PMID: 23900675 DOI: 10.1007/s13277-013-0908-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Accepted: 05/31/2013] [Indexed: 01/08/2023] Open
Abstract
Cytotoxic T lymphocyte antigen 4 (CTLA-4) gene +49G>A polymorphism was implicated to be associated with risk of malignant bone tumors, but the finding was inconclusive owing to the limited sample of a single study. The objective of the current study was to conduct a pooled analysis of four previously published studies to investigate the association between CTLA-4 +49G>A polymorphism and the risk of malignant bone tumors. Data were extracted, and the pooled odds ratio (OR) with the corresponding 95% confidence interval (95% CI) was calculated to assess the association. Those four published studies included a total of 2,165 subjects. The pooled results indicated that CTLA-4 +49G>A polymorphism was significantly associated with risk of malignant bone tumors (AA versus GG: OR = 2.24, 95% CI 1.67-2.99, P < 0.001; AA/GA versus GG: OR = 1.35, 95% CI 1.14-1.61, P = 0.001; AA versus GG/GA: OR = 2.00, 95% CI 1.53-2.62, P < 0.001). Stratified analyses by tumor type showed that CTLA-4 +49G>A polymorphism was associated with risks of both osteosarcoma (AA versus GG: OR = 2.23, 95% CI 1.45-3.43, P < 0.001; AA/GA versus GG: OR = 1.35, 95% CI 1.04-1.75, P = 0.024; AA versus GG/GA: OR = 2.00, 95% CI 1.34-2.98, P = 0.001) and Ewing's sarcoma (AA versus GG: OR = 2.24, 95% CI 1.51-3.31, P < 0.001; AA/GA versus GG: OR = 1.36, 95% CI 1.07-1.72, P = 0.011; AA versus GG/GA: OR = 2.01, 95 % CI 1.39-2.89, P < 0.001). Therefore, results from the current pooled analysis suggest that CTLA-4 +49G>A polymorphism is associated with risk of malignant bone tumors, including osteosarcoma and Ewing's sarcoma.
Collapse
|
12
|
Georges S, Chesneau J, Hervouet S, Taurelle J, Gouin F, Redini F, Padrines M, Heymann D, Fortun Y, Verrecchia F. A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. Eur J Cancer 2013; 49:2253-63. [PMID: 23490646 DOI: 10.1016/j.ejca.2013.02.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Revised: 01/11/2013] [Accepted: 02/14/2013] [Indexed: 12/22/2022]
Abstract
BACKGROUND Osteosarcoma is the most common primary malignant bone tumour in children and adolescents for whom the prognosis remains unfavourable despite treatment protocols that combine chemotherapy and surgery. Metalloproteinases decisively contribute to cancer development and promotion by regulating cell growth, angiogenesis or inflammation. However, their role in osteosarcoma remains still unknown. METHODS A screening of a large panel of metalloproteinases and their inhibitors, carried out in osteolytic (K7M2 and POS-1) or osteoblastic (MOS-J) mouse osteosarcoma models, shows that a member of a family of cell surface metallopeptidases, A Disintegrin And Metalloproteinase 12 (ADAM12), is highly expressed in the K7M2 and POS-1 cell lines and weakly expressed in the MOS-J cell line. To investigate whether ADAM12, involved in several pathologic conditions characterised by abnormal cell growth, plays a role in osteosarcoma tumour growth, ADAM12 was overexpressed in MOS-J and downregulated in K7M2 cells. RESULTS In vivo experiments demonstrated that ADAM12 favours tumour growth, leading to a significant modification in animal survival. In vitro assays showed that ADAM12 knockdown in K7M2 cells slows cell proliferation. In addition, the study of microarchitectural parameters, assessed by micro-computed tomography (CT) analysis, showed that ADAM12 favours bone osteolysis, as demonstrated both in an ADAM12 overexpressing (MOS-J) and a knockdown (K7M2) model. Histological analysis showed that ADAM12 inhibited osteoblast activity and therefore enhanced bone resorption. CONCLUSIONS Our study demonstrates that ADAM12 expression not only favours tumour growth but also associates enhanced osteolysis with a significant reduction in animal survival, suggesting that ADAM12 could be a new therapeutic target in osteosarcoma.
Collapse
Affiliation(s)
- Steven Georges
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Julie Chesneau
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Soizic Hervouet
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Julien Taurelle
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - François Gouin
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Françoise Redini
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Marc Padrines
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Dominique Heymann
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Yannick Fortun
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Institut Universitaire de Technologie, Angers, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
| | - Franck Verrecchia
- LUNAM Université, France; INSERM, UMR-S 957, Nantes, France; Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France; CHU de Nantes, Nantes, France; Equipe labellisée Ligue contre le Cancer 2012, Nantes, France.
| |
Collapse
|
13
|
Jiang L, Tao C, He A. Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis. Tumour Biol 2013; 34:1037-43. [PMID: 23341181 DOI: 10.1007/s13277-012-0643-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2012] [Accepted: 12/26/2012] [Indexed: 02/07/2023] Open
Abstract
Osteosarcoma and Ewing's sarcoma are the two most common primary malignant bone tumors, and findings of prognostic factors are important for clinicians to decide treatment options. High p53 expression has been implicated in tumor development and progression, but studies investigating the prognostic role of p53 overexpression in malignant bone tumors report conflicting findings. We performed a meta-analysis to assess the relationship between p53 overexpression and the survival of malignant bone tumors. A meta-analysis of 13 studies with a total of 703 patients was carried out to evaluate the association between p53 overexpression and overall survival (OS) and disease-free survival (DFS) in patients with malignant bone tumors. The pooled hazard ratio (HR) with its 95 % confidence interval (CI) was used as the effect size estimate. There was no between-study heterogeneity in both OS studies (I (2) = 0.0 %) and DFS studies (I(2) = 0.0 %). Overall, high p53 expression predicted both poor OS (HR 2.13, 95 % CI 1.81-2.52, P < 0.001) and poor DFS (HR 2.06, 95 % CI 1.58-2.69, P < 0.001) in patients with malignant bone tumors. Subgroup analyses by tumor types suggested that p53 expression predicted poor OS in both osteosarcoma patients (HR 2.15, 95 % CI 1.78-2.60, I (2) = 15.2 %, P < 0.001) and Ewing's sarcoma patients (HR 2.09, 95 % CI 1.47-2.97, I(2) = 0.0 %, P < 0.001). Besides, p53 expression also predicted poor DFS in both osteosarcoma patients (HR 2.38, 95 % CI 1.60-3.52, I(2) = 0.0 %, P < 0.001) and Ewing's sarcoma patients (HR 1.83, 95 % CI 1.28-2.63, I(2) = 0.0 %, P = 0.001). Egger's test also did not suggest evidence for publication bias in both OS studies (P = 0.615) and DFS studies (P = 0.258). High p53 expression indicates a poorer prognosis for patients with osteosarcoma and Ewing's sarcoma.
Collapse
Affiliation(s)
- Liangdong Jiang
- Department of Orthopaedics, The Second Xiangya Hospital of Central South University, No. 139 People's Road, Changsha, 410011, China
| | | | | |
Collapse
|
14
|
Current World Literature. Curr Opin Oncol 2012; 24:454-60. [DOI: 10.1097/cco.0b013e328355876c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|